Provided is the use of cystamine, cysteamine or a calcineurin inhibitor for the treatment of a MeCP2 (methyl CpG binding protein 2)-associated disorder. Preferrred calcineurin inhibitors include calcipressins, tacrolimus and tacrolimus analogs, cyclosporine A and cyclosporine A analogs, LxPV proteins, 2,6-diaryl-substituted pyrimidine derivatives or FK506-binding proteins. Examples of MeCP2-associated disorders include Rett syndrome, autism, pervasive development disorder, nonsyndromic mental retardation, idiopathic neonatal encephalopathy and idiopathic cerebral palsy.
Treatment of mecp2-associated disorders